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XX female gonadal dysgenesis (XX-GD) is a rare, genetically heterogeneous disorder characterized by lack of spontaneous pubertal devel-
opment, primaryamenorrhea,uterinehypoplasia, andhypergonadotropichypogonadismasa result of streakgonads.Most casesareunex-
plainedbut thought tobe autosomal recessive.We elucidated the genetic basis ofXX-GD in ahighly consanguineous Palestinian family by
using homozygosity mapping and candidate-gene and whole-exome sequencing. Affected females were homozygous for a 3 bp deletion
(NM_016556.2, c.600_602del) in the PSMC3IP gene, leading to deletion of a glutamic acid residue (p.Glu201del) in the highly conserved
C-terminal acidic domain. Proteasome 26S subunit, ATPase, 3-Interacting Protein (PSMC3IP)/Tat Binding Protein Interacting Protein
(TBPIP) is a nuclear, tissue-specific protein with multiple functions. It is critical for meiotic recombination as indicated by the known
role of its yeast ortholog,Hop2. Through theC terminus (not present in yeast), PSMC3IP also coactivates ligand-driven transcriptionmedi-
ated by estrogen, androgen, glucocorticoid, progesterone, and thyroid nuclear receptors. In cell lines, the p.Glu201delmutation abolished
PSMC3IP activation of estrogen-driven transcription. Impaired estrogenic signaling can lead to ovarian dysgenesis both by affecting the
size of the follicular pool created during fetal development and by failing to counteract follicular atresia during puberty. PSMC3IP joins
previous genes known to be mutated in XX-GD, the FSH receptor, and BMP15, highlighting the importance of hormonal signaling in
ovarian development and maintenance and suggesting a common pathway perturbed in isolated XX-GD. By analogy to other XX-GD
genes, PSMC3IP is also a candidate gene for premature ovarian failure, and its role in folliculogenesis should be further investigated.Sex determination of the embryo is established bymultiple
molecular events that direct the development of germ
cells, their migration to the urogenital ridge, and the
formation of either a testis or an ovary from the indifferent
or bipotential gonad.1,2 Aberrations of this process can
result in major structural genital anomalies, ambiguous
genitalia, gonadal dysgenesis (GD), and infertility (re-
viewed in Biason-Lauber3). Ovarian development was orig-
inally considered to be a default pathway reflecting lack of
SRY. Although a number of genes are now known to be
involved in early ovarian development (e.g., WNT4 [MIM
3603490], NR0B1/DAX1 [MIM 300473], FOXL2 [MIM
605597], and RSPO1 [MIM 609595]), the details of female
sex determination are not as well understood as male sex
determination.3 Elucidating the molecular defects under-
lying disorders of sex development (DSD) has provided
critical insights into this process. Hypergonadotropic com-
plete ovarian insufficiency (OI) with normal karyotype (46,
XX), also known as XX female gonadal dysgenesis (XX-GD
[MIM 233300]) is a rare, genetically heterogeneous dis-
order. It represents the severe end of the spectrum of
ovarian insufficiency, which can range from lack of spon-
taneous pubertal development to premature menopause
before age 40. XX-GD females have streak gonads, leading
to low estrogen and progesterone levels and subsequently1Division of Pediatric Endocrinology, Hadassah Hebrew University Medical Sch
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able, but the common presentation is a lack of sponta-
neous pubertal development, primary amenorrhea, and
uterine hypoplasia. Known causes of isolated XX-GD
include recessive mutations in the follicle-stimulating
hormone (FSH) receptor gene (FSHR [MIM 136435]), severe
X-linked recessive mutations in the growth and differenti-
ation factor BMP15 (MIM 300247), and both recessive and
dominant mutations in the NR5A1/SF-1 (MIM 184757)
transcriptional regulator.4,5 Syndromes featuring XX-GD
include XX-GD with immunodeficiency and pulmonary
fibrosis (MIM 611926), XX-GD with short stature and re-
current metabolic acidosis (MIM 605756), and congenital
muscular dystrophy with infantile cataracts and GD
(MIM 254000). Ovarioleukodystrophy (MIM 603896), a
leukoencephalopathy with vanishing white matter that is
associated with XX-GD, is caused by mutations in the
EIF2B2 (MIM 606454), EIF2B4 (MIM 606687) and EIF2B5
(MIM 603945), genes, which encode subunits of the trans-
lation initiation factor EIF2B (reviewed in Fogli and Boesp-
flug-Tanguy6). Perrault syndrome (MIM 233400), which
also includes sensorineural deafness and, in some families,
neurological manifestations, can be caused by mutations
inHSD17B4 (MIM 610860), which encodes a 17-beta-estra-
diol dehydrogenase involved in peroxisomal fatty acidool, Jerusalem 91120 Israel; 2Hebrew University Medical School, Jerusalem
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Figure 1. XX Ovarian Dysgenesis in a Consan-
guineous Family
To simplify pedigree structure, not all family
members are indicated. Individual’s pedigree
numbers are indicated above the symbols and
their ages are indicated under the symbols. The
proband is indicated by an arrow.beta-oxidation7 and in HARS2 (MIM 600783), which
encodes the mitochondrial histidyl-tRNA synthetase.8
However, the majority of isolated XX-GD cases remain
unexplained and are thought to be caused by other auto-
somal-recessive mutations.
We report a highly consanguineous Arab Palestinian
family in which at least five females are affected with
complete XX-GD, all sharing the same clinical and labora-
tory features (Figure 1). The proband (Figure 1, IV-3) is the
youngest daughter of distantly related parents (III-1 and
III-2, Figure 1). Following normal pregnancy and delivery
(birth weight 3000 g) and normal growth and develop-
ment in childhood, she failed to develop spontaneous
puberty and at 15 years of age, breast development and
pubic hair were at Tanner stage 1 and 2, respectively.
Hormonal testing of individual IV-3 revealed high basal
gonadotropin levels (LH, 19.9 IU/L, FSH, 89.3 IU/L; normal
values are: pubertal LH, 1.0–14.7 IU/L; menopausal LH,
11.0–40.0; pubertal FSH, 3.0–21.0 IU/L; menopausal
FSH, 21.1–73.0 IU/L) that increased further during luteiniz-
ing hormone-releasing hormone (LHRH) stimulation.
Estradiol and progesterone were undetectable (estradiol <
73.4 pmol/l, progesterone < 0.64 nmol/l; normal values
for the follicular and luteal stage are 100–900 pmol/l and
1–63 nmol/l, respectively) and androgen levels were
normal (the testosterone level was 2.2 nmol/l; the normal
level is 1–3 nmol/l). Thyroid, adrenal, and growth hor-
mone functions were normal. Karyotype was that of a
normal female, 46,XX, and no SRY sequence was detected
by PCR. Abdominal ultrasound and magnetic resonance
imaging revealed uterine hypoplasia and undetectable
ovaries. Hormone replacement therapy resulted in normal
breast development and induction of regular menstrua-
tion, but uterus size remained relatively small. We subse-
quently examined the proband’s sister (IV-2, Figure 1),
who was then 18 years old and was receiving low-dose
estradiol replacement therapy for primary amenorrhea of
unknown cause. Pubertal development had commenced
only following treatment and was only partial (TannerThe American Journal of Hustage 3) as a result of insufficient estrogen
dosage and lack of progesterone replace-
ment therapy. Her laboratory and imaging
results were similar to those of the proband.
In the extended family, the proband’s father
reported that two of his paternal cousins,
both women currently in their 50s (III-5,
III-6, Figure 1), were childless. These women
also had primary amenorrhea and achievedpuberty and menarche only following hormonal replace-
ment. In both cases, the karyotype was 46,XX, and ab-
dominal ultrasounds showed hypoplastic uterus and un-
detectable ovaries. In individual III-6 these findings were
confirmed in an explorative laparotomy. In the following
year, the proband’s second cousin (IV-6) presented at age
17 years with primary amenorrhea and lack of pubertal
development. Results of laboratory and imaging studies
were similar to those of the proband. Individual IV-6 is
the child of first-cousin parents (III-3 and III-4) who are
members of the same extended family. Other adult sisters
of affected females (IV-1, IV-7, and III-7; Figure 1) are
healthy and have normal sexual development and fertility
(IV-1 and III-7). Given the high degree of consanguinity,
we hypothesized that XX-GD in this family was autosomal
recessive, as result of homozygosity by descent. Following
approval of the institutional review board and the National
Helsinki Committee for Genetic Studies, informed consent
was obtained and homozygosity mapping was performed
on all sampled individuals indicated in Figure 1. We did
not include male siblings of affected females in this anal-
ysis because, as in other XX-GDs, the phenotype might
be sex-limited. DNA extracted from blood was genotyped
with the Affymetrix GeneChip 250K Nsp SNP array. SNP
data were examined for informative genomic regions
longer than 2 Mb that were homozygous and shared
among affected women but were not homozygous for
the same allele in the unaffected sisters.
Data analysis was performed with KinSNP9 and SNP
Express.10 A single 4.8 Mb region fulfilling homozygosity
criteria was identified on chromosome 17 (40,174,841-
44,987,261 hg19). Fine mapping of this region with 27
short tandem repeat (STR) markers defined a homozygous
region of similar size (39,990,510-44,708,028 hg19) (Fig-
ure 2). Combining these results, the boundaries of the
region were 40,174,841 to 44,708,028, a 4.5 Mb region
harboring 157 genes (UCSC Genome Browser). An obvious
candidate gene in this region was BRCA1 (MIM 113705)
because it is highly expressed in oocytes,11 plays a criticalman Genetics 89, 572–579, October 7, 2011 573
Figure 2. Haplotypes in the Chromosome
17q21 Region
Individuals are numbered as in Figure 1. Selected
STR markers (of 27 genotyped) are listed telo-
meric (D17S931) to centromeric (AC16). For
PSMC3IP the following abbreviations are used:
DE, the p.Glu201del mutation; wt, wild-type
sequence. The disease-associated haplotype is
shown in white, and the homozygous region
shared by all affected individuals is boxed in
red. Primer sequences for all STRs and for
PSMC3IP sequencing are detailed in Table S1.role in meiosis,12,13 and functions as a ubiquitin ligase of
estrogen receptor (ER)a.14 BRCA1 sequencing of individ-
uals IV-2 and IV-6 revealed no mutations (primer se-
quences are detailed in Table S1, available online). After
ruling out BRCA1, other genes in the candidate interval
were assessed for function and tissue expression relevant
to XX-GD. We performed Sanger sequencing of MEOX1
(MIM 600147), NAGLU (MIM 609701), UBTF (MIM
600673), and PSMC3IP (MIM 608665) (primer sequences
are detailed in Table S1). This revealed a homozygous 3 bp
deletion in the PSMC3IP gene (Figure 3A), NM_016556.2
(PSMC3IP_v001):c.600_602del (p.Glu201del). This 3 bp
deletion is predicted to result in deletion of one of two
adjacent, highly conserved glutamate residues at positions
200 and 201 and is designated as PSMC3IP p.Glu201del
(Figure 3B). PSMC3IP c.600_602del was not found in
genomic DNA of 254 chromosomes of healthy controls of
Arab Palestinian origin.
From genomic sequence alone, it was not possible to
determine whether the 3 bp deletion, designated c.
600_602del, altered the PSMC3IP intron7/exon 8 acceptor
splice site. Five alternative 3 bp deletions at genomic loca-
tion chr17:40,725,038-40,725,044 (hg19) could lead to the
mutant intron 7/exon8 AG/GAA sequence (Figure 3A).
These include deletions of the exon 8 acceptor splice site,
although the canonical AG remains intact in all cases
(Figure 3A). To determine whether the deletion affects
splicing, we performed RT-PCR spanning exons 5–8 on
leukocyte cDNA from affected and unaffected individuals.
Alternative splicing was not observed, suggesting the574 The American Journal of Human Genetics 89, 572–579, October 7, 2011mutation does not affect PSMC3IP splicing
(data not shown). The PSMC3IP locus partly
overlaps with theMLX gene (MIM 602976),
which is transcribed in the opposite direc-
tion, and PSMC3IP c. 600_602del corre-
sponds to a 3 bp deletion within the MLX
30 UTR, 1417 bp downstream of the MLX
stop codon and 150 bp upstream of the
MLX polyA signal. Quantitative RT-PCR of
MLX expression in leukocyte cDNA from
homozygous affected and heterozygous
and homozygous unaffected individuals
revealed no differences in MLX expression.
We conclude that the pathogenic effect ofthe 3 bp deletion is highly unlikely to be due to the altered
MLX 30 UTR sequence.
To exhaustively analyze the 4.5 Mb candidate interval,
we carried out whole-exome,massively parallel sequencing
for individuals IV-3 and IV-6 (Figure 1). Libraries prepared
from the genomic DNA of individuals IV-3 and IV-6
(Figure 1)were hybridized to biotinylated cRNAoligonucle-
otide baits from the SureSelect HumanAll ExonKit (Agilent
Technologies, Santa Clara, CA). Each exome-enriched
library was sequenced with 50 bp single-end reads on two
lanes of an ABI SOLiD 3 plus analyzer. The sequences
were aligned to the hg19 human genome assembly
(February 2009) with Burrows-Wheeler Aligner (BWA);15
Samtools16 was used to list high-quality DNA variants,
and Annovar17 was applied to this list in order to filter
out those variants listed in dbSNP130 or predicted to be
benign according to SIFT.18 The remaining variants were
then classified by Annovar as missense, nonsense, frame-
shift, or splice-site variants. To corroborate these results,
we repeated the entire analysis with the CLC Bio Genomic
Workbench (CLC Bio, Aarhus, Denmark). The proportion
of the entire exome covered bymore than five reads in indi-
viduals IV-3 and IV-6was 65% and 70%, respectively, in the
first analysis, and 63% and 68%, respectively, in the second
analysis. In both analyses, the only functional variant
shared between IV-3 and IV-6 within the homozygous
candidate region in chromosome 17, was the PSMC3IP
3 bp deletion described above (Table 1, Table S2).
PSMC3IP (Proteasome 26S subunit, ATPase, 3-Interacting
Protein) is also known as TBPIP (Tat Binding Protein
AB
Figure 3. The PSMC3IP c.600_602del Mutation, Which Encodes
the p.Glu201del Mutation
(A) Genomic sequence at the exon 8 acceptor splice junction.
Affected females are homozygous for a 3 bp deletion, eliminating
one of two adjacent glutamic acid residues (codons circled in
black). Blue bars indicate five possible deleted triads that would
lead to the mutant AGjGAA sequence resulting in p.Glu201del.
The vertical dashed line indicates the intron 7-exon 8 boundary.
The AGjGAA splice sequence is maintained in the homozygous
mutant.
(B) PSMC3IP domains and conservation of the acidic C-terminal
region. Yeast Hop2 and its mammalian ortholog, PSMC3IP, are
shown with known domains.19,20,42 Numbers below the bars
indicate the residue number. Within the conserved acidic domain,
the adjacent Glu residues are indicated in red and nonconserved
residues in green, an asterisk (*) denotes acidic residues. Acidic
domains are important for interaction with transcriptional coacti-
vators.43Interacting Protein) and is the ortholog of S. cerevisiae
Hop2. The gene encodes two protein isoforms of 217 and
205 residues and has adjacent leucine zipper and coiled-
coil domains in the middle region of the protein19 and a
C-terminal acidic domain starting at Glu200 (Figure 3B).20
This acidic domain is not present in the yeast ortholog
but is highly conserved from zebrafish to human, and
both Glu200 and Glu201 are invariant in all species (Fig-
ure 3B). Human PSMC3IP was originally described as a
transcript in the chromosome 17 BRCA1 region21 and
was later identified in a yeast two-hybrid screen for pro-
teins interacting with the glucocorticoid receptor DNA-The Americbinding domain.22 PSMC3IP encodes a nuclear protein
found at high levels in the testis of fetal and adult mouse,
rat, and human and is also present in the fetal and adult
ovary, spleen, and thymus22–24 (Figures S1 and S2). In addi-
tion to the glucocorticoid receptor, PSMC3IP binds the
DNA-binding domains of other hormone receptors, in-
cluding the estrogen receptors (ER) a and b, the thyroid
hormone receptor b1, the androgen receptor, and the
progesterone receptor. PSMC3IP acts as a coactivator of
ligand (hormone)-dependent transcription mediated by
all of these nuclear receptors.22 Deletion analysis has
shown that although the PSMC3IP leucine zipper is critical
for nuclear receptor binding, ligand-dependent tran-
scriptional coactivation cannot be localized to a single
domain.22 However, ligand-dependent transcriptional co-
activation is particularly dependent on the PSMC3IP
C-terminal region (aa 181-217), which includes Glu201
and the acidic domain22 (Figure 3B).
We therefore examined the effect of the PSMC3IP
p.Glu201del mutation on hormonal signal transduction
and specifically on the coactivation of estrogen-dependent
transcription by using the assay described by Ko et al.22 in
an ovarian carcinoma cell line IGROV1 (Figure 4)25 and a
breast cancer cell line, MCF-7. Wild-type and mutant
PSMC3IP-expression constructs were cotransfected with a
reporter construct containing a firefly luciferase gene
downstream of an estrogen-response element (ERE, Addg-
ene, Cambridge, MA), in addition to an ERa-expression
construct (Addgene, Cambridge, MA) and a Renilla lucif-
erase construct to control for transfection efficiency.
Relative luciferase activity was measured with the Dual-
Luciferase Reporter Assay System (Promega), with and
without b-estradiol treatment. Coactivation of estrogen-
dependent transcription was compared for the mutant
PSMC3IP p.Glu201del construct, the wild-type PSMC3IP
construct, and a C terminus-deleted PSMC3IP construct
previously reported to have significantly reduced
estrogen-induced activity (PSMC3IP c.541_651del, corre-
sponding to PSMC3IP p.Thr181_Pro217del)22 (Figure 4).
Whereas in IGROV1 cells wild-type PSMC3IP-induced
estrogen-dependent activity by 48% (p < 0.02), PSMC3IP
p.Glu201del had no significant coactivating activity,
similar to PSMC3IP p.Thr181_Pro217del (Figure 4). Com-
pared to wild-type PSMC3IP, under estradiol treatment
the p.Glu201del mutant had 68% less activity (p < 0.02)
in IGROV1 cells (Figure 4) and 18% less activity in
MCF-7 cells (p < 0.01).
These results demonstrate that the PSMC3IP p.Glu201del
mutation significantly impairs PSMC3IP function as an ER
coactivator, consistent with the uniformly severe pheno-
type observed in all affected females in the family
described. Combined with the genetic evidence, we con-
clude that a PSMC3IP mutation is the genetic basis for XX
hypergonadotropic ovarian dysgenesis in this family.
Hop2, the yeast ortholog of PSMC3IP, is required for
homologous pairing and recombination in meiosis26 as
part of the Hop2-Mnd1 heterodimer essential for activityan Journal of Human Genetics 89, 572–579, October 7, 2011 575
Table 1. Whole-Exome Sequencing in Two Affected Individuals
Individual
(Figure 1)
Number of DNA variants
Totala
Not in
dbSNP130.
SIFT Score
[p < 0.05]
Nonsynonymous
or Splice Junction
Variantsb
Within the
Chromosome 17
Homozygous Region
Shared by Both
Affected Individuals
IV-3 32,899 5,643 5,333 2,080 10 1
IV-6 42,328 7,060 6,678 2,252 5 1
Results shown are for analysis with BWA,15 Samtools,16 and Annovar.17
a Variants with a minimum quality score of 20, covered by at least four reads.
b Splice mutations are defined as those within 10 nt of an intron/exon junction.of Dmc1, the meiosis-specific recombinase.27 Murine
Hop2/Psmc3ip knockouts28 have defects in gametogenesis
but are otherwise normal, suggesting that PSMC3IP is not*
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Figure 4. Reduced Estrogen-Induced Transcriptional Activity of
PSMC3IP p.Glu201del
Ovarian carcinoma IGROV1 cells, which do not express the
estrogen receptor (ER),41 were cotransfected with a reporter
including luciferase downstream of an ERE (100ng), ERa (10ng),
and either an empty pcDNA3.1þ vector (Invitrogen), or one of
three forms of PSMC3IP cloned into pcDNA3.1(þ): wild-type
(WT), C-terminal deletion, p.Thr181_Pro217del, and the
p.Glu201del mutation we identified.
We used the Promega Dual-Luciferase Reporter Assay System
(Promega), in which reporter activity is normalized against a
Renilla luciferase reporter controlled by the HSV-thymidine kinase
promoter (pRL-TK). Total DNA amounts were balanced with
pcDNA3.1 vector.
Relative luciferase activity of the ERE-luciferase reporter construct
is shown for each PSMC3IP construct, with (þE2) or without (E2)
treatment with 30nM b-estradiol in RPMI medium.
The error bars indicate mean values of triplicate transfections 5
SEM, normalized to the empty vector control. For indicated
comparisons, *p < 0.02. NS is an abbreviation for not significant.
The PSMC3IP WT and p.Glu201del constructs were produced by
RT-PCR of RNA extracted from lymphocytes of a healthy indi-
vidual and the proband, respectively. Following PCR, products
were cut by restriction enzymes and ligated into the pcDNA3.1þ
(Invitrogen) multicloning-site. The p.Thr181_Pro217del construct
was produced in a similar manner, and primers were designed
specifically to remove residues 181–217 of the protein (primer
sequences are indicated in Table S1).
576 The American Journal of Human Genetics 89, 572–579, Octoberdevelopmentally essential. Female knockout mice show
severe reduction in ovarian size, tubulo-stromal hyper-
plasia, and a lack of follicles. Male knockout mice have
testicular hypoplasia, hyperplasia of interstitial cells,
a lack of spermatogenesis, and a block in meiosis I. Consis-
tent with Hop2’s role in meiosis, homologous chromo-
somes in spermatocytes of Psmc3ip knockout mice fail to
synapse, and double-strand breaks at recombination sites
are not repaired.28 The possibility of a meiotic defect in
the human patients with GD cannot be directly examined
because the affected females were diagnosed years after the
onset of meiosis. However, the p.Glu201del mutation
alters the PSMC3IP acidic domain, which is not present
in the yeast ortholog, and in the mouse, deletion of
Psmc3ip’s 36most C-terminal residues, including the entire
18 residue acidic domain, does not impair Mnd1 complex
formation or DNA binding.19 Thus, current evidence does
not indicate a direct meiotic role for the PSMC3IP acidic
domain but does not preclude the possibility that
p.Glu201del could have a meiotic effect by affecting the
overall conformation of the protein. Our direct evidence
(Figure 4) supports the hypothesis that the ovarian dysgen-
esis phenotype observed with the PSMC3IP p.Glu201del
mutation is related to impaired estrogen-dependent
transcription.
Although estrogen is not required for the initial steps in
ovarian differentiation in mammals, it plays a critical,
species-specific role in two stages of ovarian follicular
development: (1) in the formation of primordial ovarian
follicles and development of healthy oocytes within folli-
cles during fetal development and the early postnatal
period, and (2) in the postquiescence development of
follicles destined for ovulation during the reproductive
span (puberty tomenopause).29Whereas inmice estrogens
inhibit primordial follicle development,30 in primates,
development of a healthy follicle pool available for adult
ovarian function is an intrauterine estrogen-dependent
event31,32 (reviewed in Albrecht and Pepe29). Recent data
from normally progressing, second-trimester human
fetuses show that the fetal ovary expresses the machinery
required to produce and respond to estrogen, proges-
terone, and androgen signaling, including aromatase
(CYP19A1), a key enzyme in estrogen synthesis, and both
ER a and b.33 The limited existing literature on human fetal7, 2011
estradiol levels suggests that circulating estradiol levels
are high,34,35 and gene-expression data show that PSMC3IP
is expressed in the second-trimester fetal ovary (Fig-
ure S2).23 It is therefore plausible that PSMC3IP mutations
would result in reduced folliculogenesis even during fetal
development.
The second stage of follicular development commences
with puberty, which is marked by increased follicle stimu-
lating hormone (FSH) secretion. Binding of FSH receptors
that are present exclusively in developing follicles activates
estrogen production in granulosa cells, and leads to normal
ovulation. Defects in this process lead to follicular atresia
and ovarian dysgenesis and a lack of sexual development
as exemplified by individuals with FSHR mutations (MIM
233300).36 Our results raise the possibility that PSMC3IP
mutations can compromise the estrogenic pathway down-
stream of the FSHR and suggest that ovarian dysgenesis
associated with PSMC3IP mutations might be caused by
the combination of a reduced fetal follicular pool and
increased postnatal follicular atresia. This hypothesis
could be tested by appropriate mouse models with the
caveat of species-specific differences in the effect of
estrogen signaling on fetal ovarian development.
Homozygous FSHR mutations cause variable defects in
spermatogenesis but not azoospermia or complete infer-
tility.37 At this time, we cannot determine whether
PSMC3IP p.Glu201del homozygosity affects males.
Fathers III-2 and III-3 (Figure 1) of the affected individuals
are heterozygous for this mutation (Figure 2), as is a post-
pubertal male sibling of affected individuals (IV-8, Fig-
ure 1). Other postpubertal males (e.g., the four brothers
of III-3, Figure 1) have not been available for testing.
Notably, there are no reports of hypogonadism or infer-
tility among any males in the extended family. However,
this does not preclude the possibility that PSMC3IP
p.Glu201del or other mutations in PSMC3IP, especially
those primarily affecting its meiotic function, would
have such effects.
As a genemutated in complete XX-GD, PSMC3IP is also a
candidate gene for related phenotypes, including the
milder phenotype of premature ovarian failure (POF, i.e.,
secondary amenorrhea before age 40) or the opposite clin-
ical phenotype of ovarian hyperstimulation syndrome
(OHSS [MIM 608115]).38 By analogy, whereas inactivating
FSHRmutations cause ovarian dysgenesis, FSHR mutations
that increase ligand promiscuity result in OHSS.39 Also, by
analogy, severe dominant negative mutations of BMP15
cause ovarian dysgenesis, whereas milder BMP15 muta-
tions that hamper posttranslational processing and lead
to reduced amounts of mature BMP15 protein might be
associated with POF (reviewed in Persani et al.38 and
Otsuka et al.40). Identification of a PSMC3IP mutation
as a cause of ovarian dysgenesis warrants examination of
the role of this gene in folliculogenesis. Genetic analysis
of PSMC3IP in individuals with XX-DSD, POF, and OHSS
could reveal additional mutations and uncover genotype-
phenotype correlations.The AmericSupplemental Data
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